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NPC1L1 and Risk of
Gallstone DiseaseWe read with great interest the recent paper by Ference
et al. (1) using genetic variants in NPC1L1 (target for
ezetimibe) and HMGCR (target for statins) to predict the
effect of ezetimibe and statins on low-density
lipoprotein (LDL) cholesterol and risk of coronary heart
disease. Ezetimibe reduces plasma levels of LDL
cholesterol by inhibiting Niemann-Pick C1-like protein
1 (NPC1L1), a transporter responsible for cholesterol
uptake from the intestine into enterocytes and from bile
into hepatocytes in humans. In a recent study of
67,385 individuals from the general population (2), we
genotyped 4 common NPC1L1 variants, previously
associated with reduced LDL cholesterol levels, and
calculated a weighted genotype score. LDL cholesterol
decreased stepwise up to 3.5%, and risk of ischemic
vascular disease decreased up to 18% in those with the
highest versus lowest genotype scores. These ﬁndings
are in agreement with results from Ference et al. (1), and
a recent study on rare loss-of-function variants in
NPC1L1 (3). However, in our study, genotype score also
associated with a 22% increase in risk of symptomatic
gallstone disease. This is biologically plausible, because
in humans where NPC1L1 is expressed both in the
intestine and in the liver, inhibition of hepatic NPC1L1 is
likely to increase biliary cholesterol and the propensity
for gallstone formation. This raises the clinically relevant
question whether long-term treatment with ezetimibe
might increase the risk of gallstones. According to the
product insert of Zetia (Merck, Kenilworth, New Jersey),
treatment of dogs (which express hepatic NPC1L1) with
high doses of ezetimibe for a month increased biliary
cholesterol 2- to 4-fold (4), suggesting that a long-term,
on-target effect of ezetimibe monotherapy might be an
increased risk of gallstones. That said, it is reassuring
that 6 years of treatment with ezetimibe in combination
with a statin did not seem to increase the risk of
gallstones (5).Bo Kobberø Lauridsen, MD
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and Risk of Gallstone DiseaseDr. Lauridsen and colleagues raise the biologically plau-
siblehypothesis that inhibiting cholesterol absorption from
bile during treatmentwith ezetimibemay increase the risk
for symptomatic gallbladder disease (GBD). They report
that persons with a greater number of polymorphisms in
the NPC1L1 gene (target of ezetimibe) had lower low-
density lipoprotein cholesterol (LDL-C), a lower risk of
coronary heart disease, and a greater risk of GBD
(relative risk [RR]: 1.07; 95% conﬁdence interval [CI]:
1.02 to 1.15; p ¼ 0.02, comparing persons with scores
above and below 5) (1). On closer inspection of these
data, however, the effect of Niemann-Pick C1-like
protein 1 (NPC1L1) polymorphisms on the risk of GBD
appears to be limited to women in Copenhagen (women:
RR: 1.10; 95% CI: 1.03 to 1.19; p ¼ 0.01; men: RR: 1.00;
95%CI: 0.89 to 1.12; p¼ 0.83).
We therefore evaluated the effect of NPC1L1 poly-
morphisms on the risk of GBD among women in our
data (2). We did not ﬁnd any association between
NPC1L1 polymorphisms and the risk of GBD, either
alone or when combined with polymorphisms in the
gene that encodes the target of statins (RR: 1.02;
95% CI: 0.97 to 1.08; p ¼ 0.49, comparing persons
with NPC1L1 scores above and below median). Our
